J.P. Morgan is out with its report today on AmeriGroup AGP, raising its PT from $49 to $62.
In a note to clients, J.P. Morgan writes, "Our December
2011 price target of $62/share (prior $49) is derived by applying a 14.5x (prior 12.5x) multiple to our 2012 earnings estimate, which compares to our group average
2012 P/E objective of 11x. We consider a premium valuation to the full group as warranted as we believe that state program/Medicaid pure plays, such as Amerigroup, are those most likely to benefit over the longer term from the coverage expansion that will occur as a result of the health reform bill."
J.P. Morgan maintains Neutral on AGP.
At the time of posting, shares of AGP were trading at $58.78, down 0.08% from Thursday's close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.